New AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger prognostic performance than current...
Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"),...
Reinforcing its commitment to rare disease treatment access, Sentynl is transitioning its program to myTomorrows patient-centric platform. AMSTERDAM, Dec. 10, 2025...
Connected Brand Identity Simplifies Access to Innovative, Agile Solutions that Drive Momentum for Companies in the Health and Life Science...
ATLANTA, Dec. 10, 2025 /PRNewswire/ -- Veritiv Operating Company, a leader in specialty packaging distribution, facility solutions and print products and...
Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant...
Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant...
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical...
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical...
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000...
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000...
CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...
CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...
ADELAIDE, Australia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning global CRO for biotechs, has announced the launch...
ADELAIDE, Australia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning global CRO for biotechs, has announced the launch...
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H...
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H...
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ...
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ...
SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel...